Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.

This article summarized the latest R&D progress of Clocortolone Pivalate, the Mechanism of Action for Clocortolone Pivalate, and the drug target R&D trends for Clocortolone Pivalate.

The US FDA has approved Biosyngen's BST02, a TIL therapy for liver cancer, for clinical trials.

This article summarized the latest R&D progress of Clofarabine, the Mechanism of Action for Clofarabine, and the drug target R&D trends for Clofarabine.

Recently, Deciphera Pharmaceutical announced the positive top-line results of its investigational drug vimseltinib in the pivotal Phase 3 MOTION trial for patients with Tenosynovial Giant Cell Tumor (TGCT).

ERK, also known as Extracellular Signal-Regulated Kinase, is a crucial protein kinase that plays a significant role in various cellular processes within the human body.

Recently, Pfizer announced that the third adaptation of the PD-L1 monoclonal antibody Sugemalimab has been conditionally approved by the National Medical Products Administration (NMPA) of China.

This article summarized the latest R&D progress of Cocaine Hydrochloride, the mechanism of action for Cocaine Hydrochloride, and the drug target R&D trends for Cocaine Hydrochloride.

Recently, the official website of the CDE shows that the marketing authorization application for Eli Lilly's new Alzheimer's medication, donanemab, has been accepted.

The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes.

Recently, Apellis Pharmaceuticals announced that The Lancet published positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan) .

This article summarized the latest R&D progress of Dactinomycin, the Mechanism of Action for Dactinomycin, and the drug target R&D trends for Dactinomycin.